Back to Search
Start Over
PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer
- Source :
- Anticancer research. 42(3)
- Publication Year :
- 2022
-
Abstract
- This study investigated the expression and survival rates of programmed cell death ligand 1 using the tumor proportion score (TPS)and combined positive score (CPS) for recurrent/metastatic head and neck cancer administered nivolumab.Forty-seven patients with recurrent/metastatic head and neck cancer with a history of platinum-based chemotherapy who received nivolumab between June 1st, 2017, and January 31st, 2019 were included in this study.TPS and CPS were strongly correlated (r=0.546). When the TPS was high (≥40%), overall and progression-free survival were significantly better. The median overall survival was 8.5 months, median progression-free survival was not reached, and the 1-year progression-free survival rate was 71.4%. However, there was no significant difference in overall and progression-free survival between the groups with high CPS (≥20).This is the first report to show a strong correlation between TPS and CPS. High TPS (40% or higher) may be used as a predictor of prognosis and efficacy. Further studies are warranted to determine the use of the CPS as a biomarker.
- Subjects :
- Adult
Aged, 80 and over
Male
Cancer Research
Time Factors
Squamous Cell Carcinoma of Head and Neck
General Medicine
Middle Aged
B7-H1 Antigen
Progression-Free Survival
Nivolumab
Oncology
Head and Neck Neoplasms
Humans
Female
Neoplasm Recurrence, Local
Immune Checkpoint Inhibitors
Aged
Neoplasm Staging
Retrospective Studies
Subjects
Details
- ISSN :
- 17917530
- Volume :
- 42
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Anticancer research
- Accession number :
- edsair.doi.dedup.....6ee972118c6f6a9b19a0a69525711189